Our data show that the EGFR inhibitor erlotinib was effective in the prevention of EGFR+/ER- breast cancers, but not EGFR-/ER+ breast cancers, in BRCA1-mutant mice (Figure 7 and Table 1). The gene discussed is BRCA1; the disease is breast carcinoma.